AAA
RCUS icon

Affinity Asset Advisors’s Arcus Biosciences RCUS Stock Holding History

Affinity Asset Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300,000
Closed -$7.15M – 116
2025
Q4 		$7.15M Buy
+300,000
New +$6.12M 0.41% 53

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Affinity Asset Advisors's RCUS Position: Q1 2026 in Review

Affinity Asset Advisors sold out of Arcus Biosciences (RCUS) in Q1 2026, closing a stake of 300,000 shares — an estimated $7.15M sold.

Affinity Asset Advisors first reported a position in RCUS in Q4 2025 and held it in 1 quarter. The position peaked at $7.15M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Affinity Asset Advisors reported no remaining Arcus Biosciences position as of Q1 2026 after selling out during the quarter.
  • Affinity Asset Advisors sold 300,000 Arcus Biosciences shares in Q1 2026, an estimated $7.15M.
  • Affinity Asset Advisors first reported a position in Arcus Biosciences in Q4 2025 and held it in 1 quarter.
  • Affinity Asset Advisors's Arcus Biosciences position peaked at $7.15M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.